Undecimal Bio

Company Overview

Snapshot

Founded in July 2025, Undecimal Bio operates with 1–10 employees. The company has secured funding across one round from two investors, including Entrée Capital and Harel Insurance & Finance, with its latest funding round occurring in January 2026.

Business overview

Undecimal Bio is an early-stage biotechnology company focused on developing AI-enabled technologies to enhance the scalability and reproducibility of RNA delivery for therapeutic research and development. The company's core technology combines RNA-delivery development with AI-assisted biological data generation and modeling. It serves the pharmaceutical and biotechnology R&D sectors, particularly teams engaged in developing RNA therapeutics.

Company Intelligence Q&A

What is Undecimal Bio's primary focus?

Undecimal Bio develops AI-enabled technologies to industrialize RNA delivery, aiming to make it more scalable and reproducible for therapeutic research and development.

When was Undecimal Bio founded?

Undecimal Bio was founded in July 2025.

Which investors participated in Undecimal Bio's funding round?

In January 2026, Undecimal Bio received funding from Entrée Capital and Harel Insurance & Finance.

What is the employee count for Undecimal Bio?

Undecimal Bio currently has 1–10 employees.

What markets does Undecimal Bio serve?

Undecimal Bio primarily serves pharmaceutical and biotechnology R&D teams that are developing RNA therapeutics.